JP2015536951A5 - - Google Patents

Download PDF

Info

Publication number
JP2015536951A5
JP2015536951A5 JP2015540852A JP2015540852A JP2015536951A5 JP 2015536951 A5 JP2015536951 A5 JP 2015536951A5 JP 2015540852 A JP2015540852 A JP 2015540852A JP 2015540852 A JP2015540852 A JP 2015540852A JP 2015536951 A5 JP2015536951 A5 JP 2015536951A5
Authority
JP
Japan
Prior art keywords
seq
nos
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015540852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015536951A (ja
JP6506172B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/068385 external-priority patent/WO2014074470A1/en
Publication of JP2015536951A publication Critical patent/JP2015536951A/ja
Publication of JP2015536951A5 publication Critical patent/JP2015536951A5/ja
Priority to JP2019063358A priority Critical patent/JP6926138B2/ja
Application granted granted Critical
Publication of JP6506172B2 publication Critical patent/JP6506172B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015540852A 2012-11-06 2013-11-05 黄色ブドウ球菌(S.aureus)関連性疾患を治療する方法 Active JP6506172B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019063358A JP6926138B2 (ja) 2012-11-06 2019-03-28 黄色ブドウ球菌(S.aureus)関連性疾患を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723128P 2012-11-06 2012-11-06
US61/723,128 2012-11-06
PCT/US2013/068385 WO2014074470A1 (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019063358A Division JP6926138B2 (ja) 2012-11-06 2019-03-28 黄色ブドウ球菌(S.aureus)関連性疾患を治療する方法

Publications (3)

Publication Number Publication Date
JP2015536951A JP2015536951A (ja) 2015-12-24
JP2015536951A5 true JP2015536951A5 (https=) 2016-12-22
JP6506172B2 JP6506172B2 (ja) 2019-04-24

Family

ID=50685101

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015540852A Active JP6506172B2 (ja) 2012-11-06 2013-11-05 黄色ブドウ球菌(S.aureus)関連性疾患を治療する方法
JP2019063358A Active JP6926138B2 (ja) 2012-11-06 2019-03-28 黄色ブドウ球菌(S.aureus)関連性疾患を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019063358A Active JP6926138B2 (ja) 2012-11-06 2019-03-28 黄色ブドウ球菌(S.aureus)関連性疾患を治療する方法

Country Status (13)

Country Link
US (3) US9845348B2 (https=)
EP (1) EP2928490B1 (https=)
JP (2) JP6506172B2 (https=)
KR (3) KR20210083389A (https=)
CN (2) CN112316135A (https=)
AU (2) AU2013341421A1 (https=)
BR (1) BR112015010126B1 (https=)
CA (1) CA2890385C (https=)
ES (1) ES2912267T3 (https=)
MX (1) MX367082B (https=)
RU (1) RU2661406C2 (https=)
SG (2) SG11201503231YA (https=)
WO (1) WO2014074470A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014100111A (ru) 2011-06-10 2015-07-20 МЕДИММЬЮН, ЭлЭлСи МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
HRP20201370T1 (hr) 2011-11-07 2020-11-27 Medimmune Limited Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
BR112015010125A2 (pt) * 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
KR20210083389A (ko) * 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
JP7525471B2 (ja) 2018-07-24 2024-07-30 メディミューン,エルエルシー S.アウレウス(S.aureus)クランピング因子A(ClfA)に対する抗体
TWI895248B (zh) 2018-10-09 2025-09-01 美商麥迪紐有限責任公司 針對金黃色葡萄球菌白血球毒素的抗體
BR112021006622A2 (pt) 2018-10-09 2021-07-20 Medimmune, Llc combinações de anticorpos anti-staphylococcus aureus
CN113811544A (zh) 2019-03-13 2021-12-17 免疫医疗有限责任公司 减少定殖患者中的金黄色葡萄球菌感染
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080131457A1 (en) * 2006-06-12 2008-06-05 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
JP5658564B2 (ja) * 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
EP2453881A2 (en) * 2009-07-16 2012-05-23 Georgia Health Sciences University Research Institute, Inc. Porous-wall hollow glass microspheres as carriers for biomolecules
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
AU2012214677B2 (en) * 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
PT2673373T (pt) * 2011-02-08 2018-12-05 Medimmune Llc Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização
BR112015010125A2 (pt) 2012-11-06 2017-08-22 Medimmune Llc Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
KR20210083389A (ko) * 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2017075188A2 (en) 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody

Similar Documents

Publication Publication Date Title
JP2015536951A5 (https=)
JP2016507470A5 (https=)
RU2015121617A (ru) Способы лечения заболеваний, ассоциированных с s. aureus
JP2014508748A5 (https=)
JP2019510478A5 (https=)
HRP20182017T4 (hr) Protutijela koja specifično vežu alfa toksin koji stvara staphylococcus aureus i postupci uporabe
JP2015504421A5 (https=)
JP2014533239A5 (https=)
JP2017507652A5 (https=)
JP2019505527A5 (https=)
JP2009225799A5 (https=)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2014205674A5 (https=)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2016529255A5 (https=)
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
JP2013198490A5 (https=)
RU2014101707A (ru) АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
JP2015509960A5 (https=)
JP2015530971A5 (https=)
JP2016530223A5 (https=)
JP2017530722A5 (https=)
HRP20170041T1 (hr) Anti-c5a vezujuće grupe s visokom blokirajućom aktivnošću
JP2015533795A5 (https=)
JP2013506428A5 (https=)